HPK traded down -10.29% to $7.41 during Wednesday’s regular session, versus a prior close of $8.26. The decline accelerated in afternoon trading after US-Iran peace-deal headlines sent WTI crude down more than 5% toward $80.61, hitting high-beta shale E&P names hardest.

MAAS is down -19.34% to $16.85 in regular trading on Aug. 12, versus a previous close of $20.89. The move built on premarket weakness and deepened through the session; by midday shares were already off -16.85% to $17.37.

Selected price target: $2.00 per share, roughly 160% above Inovio's recent trading level near $0.77. Strongest bullish factor: The FDA is reviewing Inovio's lead DNA medicine candidate, INO-3107, with a PDUFA target action date of October 30, 2026.

Both GLD and IAU provide direct exposure to physical gold bullion and track the LBMA Gold Price, resulting in nearly identical underlying performance profiles. Structural differences center on expense ratios, with GLD at 0.40% and IAU at 0.25%, creating a persistent cost advantage for long-term holders of IAU .

Inovio Pharmaceuticals (NASDAQ: INO) is scheduled to report second-quarter 2026 results after the U.S. market close on August 12, 2026, followed by a conference call at 4:30 p.m. Eastern Time. The consensus estimate calls for a net loss of $0.24 per share, narrower than the $0.61 loss reported in the prior-year quarter.

INO shares fell approximately 33.5% from a closing price of $1.16 on July 13, 2026, to an intraday price near $0.77 on August 12, 2026. The sharpest sell-off followed INOVIO's late-July pricing of a $20 million public offering of common stock and warrants, which triggered immediate dilution concerns.

Multiple late-stage oncology readouts, including five-year Phase 2 melanoma data and Phase 3 adjuvant melanoma results for intismeran, are expected in 2026 and could shape sentiment around the mRNA platform's expansion into cancer therapies. Potential regulatory approvals for mNEXSPIKE in select markets, flu vaccine, and flu + COVID-19 combination candidates position the company for portfolio diversification beyond its established COVID-19 franchise.

Selected price target: $7.00 per share, the most widely cited lower-bound analyst target and a round-number level sitting just above the stock's 52-week high of $6.55. Starting point: SANA closed the most recent regular session near $3.79, meaning a move to $7 would require roughly 85% upside.

Selected price target: $60, approximately 47% above the recent $40.91 close and essentially in line with the consensus analyst price target of about $60. Strongest bullish factor: A late-stage pipeline led by DT120 in depression and anxiety, supported by U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for generalized anxiety disorder (GAD).

The selected price target is $7 , roughly 81% above the latest close of $3.87 and about 35% above the 52-week high of $5.17. Wall Street support is a key bullish factor: the low end of current analyst price targets clusters near $6 to $7, with consensus estimates well above that level.

BAC traded near $64.37 in mid-August 2026, roughly 8.2% above the July 13, 2026 close of $59.50, extending a steady 30-day advance. Second-quarter results released July 14 beat expectations, with EPS of $1.21, revenue of $31.6 billion, and net income up 27% year over year.

SEALSQ Corp (LAES) operates as a subsidiary of WISeKey International Holding AG (WKEY), focusing on semiconductors and post-quantum security solutions. Both companies target cybersecurity, IoT, and quantum-resistant technologies, with recent press releases highlighting partnerships, executive appointments, and product developments in the past month.

As of the August 12, 2026 intraday session, LAES traded near $2.60, down about 4% from the July 13, 2026 close of $2.71 over the trailing 30 days. The modest move keeps the stock in consolidation below its 50-day and 200-day moving averages, within a 52-week range of $1.99 to $8.71.

ExxonMobil (XOM) surged approximately +14.9% over the past 30 days, climbing from $136.54 on June 26 to $156.94 by July 24, 2026. The rally was primarily fueled by escalating geopolitical tensions between the U.S. and Iran, which drove crude oil prices sharply higher and disrupted Strait of Hormuz shipping lanes.

GLD gained approximately 10.7% over the last 30 days, rebounding from a multi-month nadir near $367 to trade above $406 per share. A sharply weaker-than-expected US employment report for July triggered a meaningful repricing of Federal Reserve rate expectations, reducing the opportunity cost of holding non-yielding gold.

Newmont Corporation (NEM) shares surged approximately 28.8% over the past 30 days, climbing from $93.10 on July 13 to $119.89 as of August 12, 2026. A powerful gold-price breakout — with COMEX gold rallying over 7% in a single week toward $4,400 per ounce — served as the primary catalyst for the mining sector's broad advance.

Eagle Capital Growth Fund, Inc. (GRF) is an actively managed closed-end fund pursuing long-term growth through a concentrated portfolio of approximately 29 U.S. equity holdings. The portfolio is heavily tilted toward Financial Services (37% of assets) and Consumer Cyclical (24%), with top holdings including Markel, Alphabet, and T. Rowe Price collectively representing a substantial portion of total assets.

Beyond Air (XAIR) shares declined approximately 23% over the past 30 days, falling from $7.49 on July 13 to $5.75 as of August 12, 2026. The stock posted a steeper loss of roughly 46-52% over the last quarter, reflecting persistent pressure from Nasdaq compliance concerns, a 1-for-20 reverse stock split, and ongoing cash burn.

SHEL has gained approximately 7.5% over the past 30 days, climbing from $83.98 on July 13 to $90.28 as of August 12, 2026, supported by an exceptional second-quarter earnings report. Shell's Q2 adjusted earnings more than doubled year-over-year to $9.84 billion, handily beating the consensus estimate of $8.92 billion and marking the company's second-highest quarterly profit on record.

UAMY plunged -21.73% on Wednesday, falling from a prior close of $6.58 to $5.15, with the selloff beginning in premarket trading and accelerating during the regular session. The primary catalyst was a deeply disappointing Q2 2026 earnings report released after Monday's close: revenue of $7.9M missed consensus estimates by roughly $13.8M as antimony average selling prices collapsed -52% year-over-year to $13.70 per pound.